METHODS FOR IDENTIFYING PATIENTS WITH AN INCREASED LIKELIHOOD OF HAVING OVARIAN CANCER AND COMPOSITIONS THEREFOR

• US 20090075307A1
• Filed: 10/30/2008
• Published: 03/19/2009
• Est. Priority Date: 01/27/2006
• Status: Abandoned Application

• Current Assignee: Tripath Imaging Incorporated (Becton, Dickinson & Co)
• Original Assignee: Tripath Imaging Incorporated (Becton, Dickinson & Co)
• Inventors: Fischer, Timothy J., Groelke, John W., Cheek, Robert L., Malinowski, Douglas P., He, Qin, Whitehead, Clark M.
• Application Number:
  US12/261,330
• Publication Number:
  US 20090075307A1
• Time in Patent Office: Days
• US Class Current: 435/7.920
• CPC Class Codes: G01N 33/57449 of ovaries

Abstract

Screening methods for identifying patients with an increased likelihood of having ovarian cancer are provided. The screening methods involve the detection of expression of a plurality of biomarkers in a body sample, wherein overexpression of the biomarkers is indicative of an increased likelihood of having ovarian cancer. The screening methods may further comprise a two-step analysis. Biomarkers of interest include genes and proteins that are, for example, involved in defects in DNA replication/cell cycle control, cell growth and proliferation, escape from apoptosis, angiogenesis or lymphogenesis, or the mechanisms of cancer cell motility and invasion. In some aspects of the invention, expression of a biomarker is detected at the protein level using a biomarker-specific antibody or at the nucleic acid level using nucleic acid hybridization techniques. Methods for detecting ovarian cancer in patients are further disclosed herein. Kits for practicing the methods of the invention are further provided.

Claims

1. A single-step screening method for identifying patients with an increased likelihood of having ovarian cancer, the method comprising detecting the expression level of two biomarker proteins in a body sample, wherein the biomarker proteins are HE4 and CA125, and wherein overexpression of at least one of the biomarker proteins is indicative of the patient having an increased likelihood of having ovarian cancer.

2. The method of claim 1, wherein the body sample is a blood or serum sample.

3. The method of claim 1, wherein the expression level of each of the two biomarker proteins is compared to the expression level of each of the two biomarker proteins in a normal patient population.

4. The method of claim 1, wherein expression of the two biomarker proteins is detected using at least one antibody that specifically binds to HE4 and at least one antibody that specifically binds to CA125.

5. The method of claim 4, wherein expression of the two biomarker proteins is detected using an ELISA format or a multiplex bead-based immunoassay.

6. The method of claim 1, wherein the screening method is performed in an automated, semi-automated, or manual fashion.

7. The method of claim 1, wherein the method is used to detect early-stage ovarian cancer.

8. The method of claim 1, wherein the patients screened in accordance with the method of claim 1 are asymptomatic and have a family history of ovarian cancer or clinical risk factors indicating a high-risk for developing ovarian cancer.

9. The method of claim 1, wherein the screening method is performed in a population of post-menopausal female patients.

10. The method of claim 1, wherein patients identified as having an increased likelihood of having ovarian cancer are further subjected to additional diagnostic testing to determine if the patient has ovarian cancer, wherein the additional diagnostic testing is selected from the group consisting of pelvic examination, transvaginal ultrasound, CT scan, MRI, laparotomy, laparoscopy, and tissue sample biopsy.

11. The method of claim 10, wherein patients identified as having an increased likelihood of having ovarian cancer that are determined not to currently have ovarian cancer are further monitored on a regular basis for the development of ovarian cancer.

12. The method of claim 1, wherein the sensitivity of the screening method for identifying patients with an increased likelihood of having ovarian cancer is at least 75%.

13. The method of claim 1, wherein the specificity of the screening method for identifying patients with an increased likelihood of having ovarian cancer is at least 75%.